← boardnext 2026-10-30
ADCT
ADC Therapeutics S.A.distress 3/10 · well-funded / low risk$1.22-2%today-75% from 52w high
adctherapeutics.com188 employeesFounded 2011Epalinges, SwitzerlandDrug Manufacturers - Specialty & Generic
Oncology 2
Lead: r/r DLBCL · target CD20
Revenue
$21M
Liquidity
$231M
Runway
2.0 yrs
Shares 1y
+13%
Price & events
-68.0% over 6M
CatalystRating changeDilutionFinancingdashed = today
-2.0%
1D
-10.0%
1W
+5.7%
1M
-69.3%
3M
-66.3%
6M
-62.0%
1Y
-68.5%
2Y
-94.4%
5Y
-96.2%
All
Overview
- Market Cap
- $154.54M
- Volume
- 23.11K
- 52 Week Range
- $0.98 – $4.88
- Total Shares
- 127.19M
- Float Shares
- 100.41M
- Short %
- 5.56%
- % Held by Insiders
- 14.47%
- % Held by Institutions
- 67.84%
- RVOL
- 0.02x
- Beta
- 1.88
Pipeline stages · 2 programs
Loncastuximab Tesirine
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
ADCT-601, Gemcitabine
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 4 trials · 2 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-10-30 Estimated 50% readout ~2026-11-29 | Phase 1 | Loncastuximab Tesirine, Polatuzumab Vedotin, Glofitamab | B-Cell Non-Hodgkin Lymphoma, Relapsed B-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma | — | recruiting |
| 2026-12 Estimated 50% readout ~2026-12-31 | Phase 1 | Loncastuximab Tesirine | Diffuse Large B-Cell Lymphoma, High-grade B-cell Lymphoma | — | recruiting |
| 2026-03-31 | Phase 3 | Loncastuximab Tesirine, Rituximab, Gemcitabine | Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma | 440 | active not recruiting |
| 2025-04-17 | Phase 1 | ADCT-601, Gemcitabine | Advanced Solid Tumors | 128 | terminated |
Catalyst news & presentations · 6
- fourth quarter of 2026Guided 70%regulatory submissionFiled (NDA/BLA)ZYNLONTA · Planned sBLA submissionSEC 8-K
- by the end of 2026Guided 40%readoutPhase 1ZYNLONTA · LOTIS-7 trial data evaluating ZYNLONTA in combination with glofitamabSEC 8-K
- August 2026Estimated 45%regulatory submissionFiled (NDA/BLA)ZYNLONTA · Pre-sBLA meeting with FDA to discuss regulatory path for ZYNLONTA in combination with rituximabSEC 8-K
- 2026-08-05Estimated 45%earningsEarningsEarnings releaseyahoo
- 2026-06-03readoutPhase 3ZYNLONTA · Topline data from Phase 3 LOTIS-5 trialSEC 8-K
- December 3, 2025readoutPhase 1/2ZYNLONTA, glofitamab · Updated data from ongoing LOTIS-7 Phase 1b trial.SEC 8-K
Approved drugs (1)
- ZYNLONTALONCASTUXIMAB TESIRINE-LPYL2021 · Prescription
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
buy · target $5 (+312% upside) · 3 analysts
- 2026-06-08HC Wainwright & Co.Buy → Neutral
- 2026-06-04RBC CapitalOutperform → Sector Perform
- 2026-05-05RBC CapitalOutperform
- 2026-05-05HC Wainwright & Co.Buy
- 2026-03-23HC Wainwright & Co.Buy
- 2025-10-16HC Wainwright & Co.Buy
Competitors — CD20
Recent news
- 2026-07-21ADC Therapeutics (NYSE:ADCT) Shares Down 6.3% - Time to Sell? - MarketBeat
- 2026-07-02ADC Therapeutics (ADCT) CEO receives 675,000 RSU equity award in Form 4 filing - Stock Titan
- 2026-07-02ADC Therapeutics (ADCT) grants 221,100 RSUs to Chief Legal Officer - Stock Titan
- 2026-07-02Executive retention awards approved at ADC Therapeutics (NYSE: ADCT) - Stock Titan
- 2026-07-02ADC Therapeutics (ADCT) grants CFO 203,700 RSUs as equity award - Stock Titan
- 2026-07-02ADC Therapeutics (ADCT) CMO awarded 213,900 RSUs, raising holdings to 896,317 shares - Stock Titan
- 2026-07-01ADC Therapeutics gives new hire 17,000-share inducement award - Stock Titan
- 2026-06-30ADC Therapeutics completes LOTIS-7 trial enrollment - grafa.com
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.